The FDA approved Abbott’s Proclaim XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN).
The Proclaim XR SCS system, approved for the treatment of chronic pain in 2019, delivers low doses of stimulation, and has been shown to provide pain relief in patients with DPN (Diabetes Care 2014;37[11]:3016-3024).
Following a successful minimally invasive trial and undergoing an implant with the Proclaim XR SCS system, patients will have the ability to